Stress Accelerates Depressive-Like Behaviors through Increase of Notch2 Expression in N141I Mutation Presenilin-2 Transgenic Mice Authors: Seung Sik Yoo, Sun Mi Gu, Kyung Tak Nam, Jeong Soon Choi, Yong Sun Lee, In Jun Yeo, Ji Eun Yu, Sanghyeon Kim, Dong Won Lee, Hyeon Joo Ham, Ju Young Chang, Jaesuk Yun, Dong Ju Son, Sang-Bae Han, Jin Tae Hong Published: 2026 ABSTRACT AbstractAlzheimer’s disease (AD) is characterized by progressive cognitive deterioration and significant depression. However, the mechanisms linking depression to AD pathology remain unclear. Here, we investigated whether Notch2 signaling mediates depression-like behaviors in presenilin-2 (PS2) N141I mutant mice, an early-onset AD model. PS2 wild-type (WT) and mutant (MT) mice aged 12-15 months were subjected to unpredictable chronic mild stress (UCMS) for 4 weeks, followed by sucrose preference, tail-hanging, and forced swimming tests. Behavioral assessments showed that UCMS exacerbated anhedonia and immobility only in PS2 MT mice. Molecular analysis revealed concomitant increases in plasma corticosterone, hippocampal γ-secretase activity, and Notch2 expression, and elevated total and phosphorylated glucocorticoid receptor levels in PS2 MT-UCMS mice. Gene expression profiling of human hippocampal datasets confirmed upregulation of NOTCH2 in Alzheimer’s disease and depression. Pharmacological inhibition of γ-secretase and Notch signaling with DAPT normalizes depressive behavior, reduces corticosterone release, attenuates GR phosphorylation, and inhibits Notch2 signaling in PS2 MT mice. These findings identify Notch2 as a pivotal mediator linking chronic stress to molecular changes associated with depression and AD, and suggest that targeting Notch2 signaling may provide therapeutic benefits for comorbid mood and neurodegenerative disorders.Keywords: Notch2, Chronic stress, Presenilin-2, Depressive-like behavior, Alzheimer’s disease, DAPT INTRODUCTION Alzheimer’s disease (AD) is the most prevalent form of dementia, distinguished by its progressive cognitive decline and neurodegeneration (Griffiths and Grant, 2023; Hampel et al., 2021; Spires-Jones and Hyman, 2014). The pathogenesis of AD is primarily driven by the accumulation of extracellular amyloid β (Aβ) plaques and intracellular neurofibrillary tangles, which contribute to neuronal loss and brain atrophy (Capilla-López et al., 2025; Nisbet and Götz, 2018; Price et al., 1995; Zhang et al., 2022). The presence of these pathologic features is attributed to mutations in genes involved in amyloid processing, including amyloid precursor protein (APP), presenilin-1 (PSEN1; PS1), and presenilin-2 (PSEN2; PS2), among others (Delabio et al., 2014; Lanoiselée et al., 2017). Of these, a substitution by Ile (N141I) at the Asn residue at position 141 of PS2 has been demonstrated to be associated with the early onset of AD (Levy-Lahad et al., 1995). The PS2 with the N141I mutation has been found to increase Aβ production, oxidative stress, and β-secretase activity (Hwang et al., 2002; Lee et al., 2006; Park et al., 2012). Furthermore, transgenic mice expressing the N141I mutant PS2 have demonstrated heightened γ-secretase activity in comparison to control mice, wherein γ-secretase plays a pivotal role in the cleavage of APP and Notch (Lee et al., 2013; Vito et al., 1996; Wolfe, 2012; Wolozin et al., 1996). Major depressive disorder (MDD) is a psychiatric disorder characterized by symptoms such as persistent depressed mood, anhedonia, and difficulty sleeping or eating, along with severe deficits in memory and learning (Belmaker and Agam, 2008; Fava and Kendler, 2000; Sáiz-Vázquez et al., 2021). MDD is moderately heritable, with earlier onset and more frequent relapses indicating a stronger family history, but genetics is not the only factor in MDD (Levinson, 2006). A variety of other variables, including stressful life events, have been found to play a role in the development of MDD (Burke et al., 2019). Neurobiologically, perturbations in stress response systems such as the hypothalamic-pituitary-adrenal (HPA) axis and the immune system are hallmarks of MDD (Cowen, 2010; Krishnan and Nestler, 2008). The present body of research indicates that glucocorticoid receptor (GR) activation, induced by stress, is particularly pronounced in the hippocampus (Xu et al., 2019). Furthermore, clinical depression patients exhibited elevated levels of GR phosphorylated at serine 211 (p-GR Ser211) in comparison to healthy individuals, thereby indicating that GR phosphorylation plays a role in the pathophysiology of MDD (Bei et al., 2009). Recent findings indicate that MDD exhibits several neurobiological features in common with AD, including neuroinflammation, dysregulation of neurotrophic factors, and impaired synaptic plasticity (Herman et al., 2016; Kino, 2015). Notably, clinical and epidemiological studies have reported that depression may serve both as a risk factor for and a prodromal symptom of AD, thereby underscoring the complex interplay between these two disorders (Bruno et al., 2020; Khairova et al., 2009). Moreover, many studies have shown that chronic stress plays an important role in the pathophysiology of both AD and depression (Butterfield et al., 2007; Charney and Manji, 2004; De Kloet et al., 2005). Activation of the HPA axis in response to chronic stress leads to elevated glucocorticoid levels, and elevated glucocorticoids activate the GR, which in turn triggers neuronal damage and neuroinflammatory responses within the hippocampus, leading to increased neuronal cell death (Anacker et al., 2011; Frodl and O’Keane, 2013; Goosens and Sapolsky, 2007; Herman et al., 2016; Kino, 2015; Krishnan and Nestler, 2008; Pariante and Lightman, 2008; Sapolsky, 1986). These stress-induced changes are believed to accelerate the onset and progression of neurodegenerative diseases and mood disorders (Bruno et al., 2020; Khairova et al., 2009). To investigate this complex interplay, selecting an appropriate stress paradigm is crucial. Unlike acute stress models, the unpredictable chronic mild stress (UCMS) protocol is widely recognized for its high translational relevance, as it closely mimics the chronic, unpredictable daily life stressors that precipitate clinical depression in humans (Burstein and Doron, 2018; Nollet, 2021; Sharma et al., 2024; Willner, 2017; Wu et al., 2022). Furthermore, because AD patients frequently exhibit HPA axis dysregulation and hypersensitivity to everyday psychosocial stress, the UCMS paradigm serves as an ideal model for evaluating how sustained, low-grade environmental stressors exacerbate depressive phenotypes and neurodegenerative progression in a genetic background predisposed to early-onset AD (Burstein and Doron, 2018; Fee et al., 2020; Milligan Armstrong et al., 2021; Quax et al., 2013; Sharma et al., 2024). Meanwhile, the Notch signaling pathway has been proposed as a key molecular mediator involved in both AD pathology and stress-induced depression-like behaviors (Kapoor and Nation, 2021; Liao et al., 2021; Woo et al., 2009). Notch is a single-pass type I trans-membrane receptor, which is expressed in high levels in the hippocampus (Berezovska et al., 1998). Weighted gene co-expression network analysis (WGCNA) revealed a significant association between Notch2 and AD (Liang et al., 2018), and a study using the APP/PS1 transgenic (Tg)-AD mice model demonstrated a relative increase in Notch2 mRNA expression in Tg mice compared to wild-type (WT) controls (Liang et al., 2018). Moreover, both Notch and APP are substrates for the γ-secretase complex, and γ-secretase inhibitors such as DAPT (N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester) and LY450139 (hydroxyvaleryl monobenzocaprolactam) have been shown to block Notch signaling and induce capillary networks in the brains of AD patients and mice models that resemble those observed in disease states (Bittner et al., 2009). Expression of Notch2 was also increased in the brains of chronic social defeat stress (CSDS) mice (Liao et al., 2021) . In addition, our previous study has demonstrated that stress increases depression-like behaviors in Tg2576-AD model mice (Yoo et al., 2025). Taken together, these findings suggest that Notch2 may serve as an important molecular hub mediating the pathological link between AD and stress-related depression, highlighting the need for further investigation of its mechanistic role and therapeutic potential. Therefore, in the present study, we aimed to determine whether Notch2 signaling is involved in depressive-like behaviors induced by chronic stress in a Tg mice expressing PS2 with N141I mutation-AD mice model. MATERIALS AND METHODS Animals Twelve- to fifteen-month-old transgenic mice expressing PS2 WT (C57BL/6J) and PS2 mutant-type (MT) showed characteristics of AD (such as deposition of Aβ and memory loss) as described previously (Hwang et al., 2002; Lee et al., 2006). The PS2 WT and MT mice were generated as described (Yoo et al., 2024). A total of four mice per group (2 males and 2 females) were used for UCMS-induced depression-related behavioral testing. A total of five mice per group (3 males and 2 females) were used for effects of DAPT on UCMS-induced depression-related behavioral testing. The age of the mice was matched to 12-15 months old. This study was conducted in strict accordance with the recommendations of the Guide for the Care and Use of Laboratory Animals, and all experiments were approved by the Guidelines for the Care and Use of Animals (Animal Care Committee of Chungbuk National University, Cheongju, Korea [CBNUA-1634-21-01]). Animal rooms were maintained at a constant temperature (21°C-24°C) and relative humidity (40%-60%) with a 12-h light/dark cycle (lights on 08:00-20:00). Mice were provided with a solid diet and tap water ad libitum. Mice experiments were performed during the light cycle (08:00-20:00). Mice were sacrificed after behavioral tests by CO2 asphyxiation. Unpredictable chronic mild stress procedure Mice were subjected to different kinds of stressors, such as: cage tilting, damp sawdust, predator sounds, placement in an empty cage, placement in an empty cage with water on the bottom, inversion of the light/dark cycle, lights on for a short period of time during the dark phase, and switching cages (Mineur et al., 2003). On average, two of these stressors were applied daily at different times and following a semi-random two-week schedule. The stress procedure lasted for four weeks prior to the behavioral testing. Stressors continued during the testing phase, except on testing days, to avoid the effects of acute stress. At least 12 h of rest was provided between a stressor and a test. The stress procedure did not involve any food or water deprivation. DAPT administration (N-[N-(3,5-Difluorophenacetyl-L-alanyl)]-S-phenylglycine t-Butyl Ester; DAPT) was purchased from Sigma Aldrich and administered as described (Dovey et al., 2001; Lanz et al., 2003a, 2003b; Netzer et al., 2010). Briefly, 100 mg of DAPT was suspended in 0.5 mL of 100% ethanol (100 mg/0.5 mL), which was then mixed with 9.5 mL of 100% Mazola corn oil (100 mg/10 mL in 5% v/v ethanol in Mazola corn oil) at the final dose of 10 mg/mL. The DAPT solution was administered subcutaneously at a dose of 10 mL/kg once daily on the first and last day and at a dose of 5 mL/kg twice daily for 12 days. Mice received 100 mg DAPT/kg/day for total 14 days. This dose was based on previous studies (Dovey et al., 2001; Imbimbo, 2008; Lanz et al., 2003b). Sucrose preference test A sucrose preference test (SPT) was performed as described in previous study (Liu et al., 2018; Yoo et al., 2025). Tail suspension test A tail suspension test (TST) was performed as described in previous study (Ruan et al., 2015; Yoo et al., 2025). Forced Swim Test A forced swim test (FST) was performed as described in previous study (Ruan et al., 2015; Yoo et al., 2025). Selection of Gene Expression Omnibus dataset and sample classification Gene Expression Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo) dataset is selected as described in previous study. The following keywords of the GSE1297 dataset were used in the GEO database: (Alzheimer’s disease) and (AD) and (hippocampal) and (Homo sapiens). The following keywords of the GSE42546 dataset were used in the GEO database: (major depression) and (depression) and (hippocampus) and (Homo sapiens). In GSE1297 dataset, we selectively used the control and AD (moderate and severe) groups datasets (Supplementary Table 1). In GSE42546 dataset, we selectively used the control and depression groups datasets (Supplementary Table 2). Differential Expression Analysis Differential expression analysis focusing on NOTCH2 was conducted using the GEO2Rweb tool provided by the National Center for Biotechnology Information (NCBI, https://www.ncbi.nlm.nih.gov/geo/geo2r/). GEO2R internally applies the limma package for linear modeling and empirical Bayes statistics. A model matrix without intercept (~0+group) was fitted to the expression data, and contrasts were calculated as AD – control for GSE1297 and depression – control for GSE42546, such that log2 fold changes (FC) represent genes up- and down-regulated in AD or depression. Differentially expressed genes (DEGs) were identified using the following thresholds: Unadjusted p-value<0.05; Absolute log2FC>0.5. Multiple testing correction was performed via the Benjamini–Hochberg method, and both raw and adjusted p-values were reported. Volcano Plot Generation A volcano plot was automatically generated within the GEO2R interface, plotting each gene according to its log2FC (x-axis) and –log10(p-value) (y-axis). Significantly upregulated genes in AD or depression were colored red, and significantly downregulated genes were colored blue. Genes not meeting statistical thresholds were shown in black. The genes NOTCH1, NOTCH2, NOTCH3, and NOTCH4 were visually identified on the plot, and NOTCH2 was highlighted based on its statistical significance (p<0.05 and |log2FC|>0.5). Gene–Disease Association Retrieval To investigate the disease associations of the NOTCH2 gene, we utilized the Comparative Toxicogenomics Database (CTD, https://ctdbase.org). The search was conducted via the CTD web interface as follows: (1) The keyword “NOTCH2” was entered into the Gene search bar on the CTD homepage; (2) In the resulting gene summary page, the “Disease” tab was selected. The disease associations were showed based on the Inference Score (Supplementary Table 3). The top-ranking diseases associated were selected and visualized as a bar, with disease names on the Y-axis and corresponding inference scores on the X-axis. Gene–gene interaction analysis Gene–gene interaction analysis was conducted using the GeneMANIA web portal (https://genemania.org/) with the following procedure. First, the organism was set to Mus musculus in the “Organism” selection menu. Next, the query gene list—Notch2, Nr3c1, Bdnf, App, and Psen2—was entered into the “Search Genes” field. Collection and preservation of brain tissues After behavioral tests, the mice were perfused with PBS with heparin under inhaled CO2 anesthetization. The brains were prepared and stored as described in previous study (Gu et al., 2018). Briefly, the mice brains were then excised from the skull and cut symmetrically in half: one-half was stored at −80°C, while the other was fixed in 4% para-formaldehyde at 4°C for 72 h before being transferred successively to 10, 20, and 30% sucrose solutions for each 24 h. Plasma collection and corticosterone ELISA assay Whole blood collected from mice was processed within two hours of collection using the following protocol. Collected blood in EDTA-treated tube was centrifuged at 2,000 × g for 15 min at room temperature, after which the plasma supernatant was transferred to a new tube. This supernatant was stored at −80°C until analyzed. An ELISA (MBS2567942) assay was used to measure corticosterone levels in the plasma, according to the manufacturer’s instructions. γ-secretase activity assay The activity of γ-secretase in hippocampal regions was determined using a commercially available γ-secretase activity kit (R&D systems, Wiesbaden, Germany) according to the manufacturer’s protocol, respectively. The fluorescence was read with a Fluostar galaxy fluorometer (excitation at 355 nm and emission at 510 nm) with Felix software (BMG Labtechnologies, Offenburg, Germany). The level of γ-secretase enzymatic activity is proportional to the fluorometric reaction, and the γ-secretase activity was expressed as relative fluorescence unit (RFU). Reverse transcription quantitative PCR (RT-qPCR) Notch2 mRNA level was measured by a quantitative real-time reverse transcription polymerase chain reaction (RT-qPCR). Total RNA extraction, cDNA synthesis, and RT-qPCR were performed as described in previous study (Yoo et al., 2024). Each sample was run with the following primer pairs: Notch2, forward primer: 5’-GACTGCCAATACTCCACCTCT-3’, reverse primer: 5’-CCATTTTCGCAGGGATGAGAT-3’; β-actin, forward primer: 5’-GGCTGTATTCCCCTCCATCG-3’, reverse primer: 5’-CCAGTTGGTAACAATGCCATGT-3’. Western blot analysis Western blotting was performed as described (Lee et al., 2008). To detect target proteins, specific antibodies against full-length Notch2 (Notch2-FL), transmembrane/intracellular region Notch2 (Notch2-NTM), p-GR (1:500, Cell Signaling Technology, MA, USA); GR, T-Tau (D-8), p-Tau (PHF-6), and β-actin (1:500, Santa Cruz, CA, USA) were used. The blots were then incubated with the corresponding conjugated secondary antibodies (1:1000); anti-mouse, anti-rabbit, and anti-goat, purchased from Santa Cruz Biotechnology Inc (Santa Cruz, CA, USA). Immunoreactive proteins were detected with an enhanced chemiluminescence Western blotting detection system. The density of the protein bands was quantified by ImageJ (Wayne Rasband, National Institutes of Health, Bethesda, MD, USA). Statistical analysis Data are presented as the means ± standard error (SE). Data were analyzed using two-way analysis of variance (ANOVA) and two-way repeated measures (RM) ANOVA, followed by the Holm–Sidak post hoc t-test using SigmaPlot 12 software (Systat Software, Chicago, IL, USA). Significance was set at p<0.05 for all tests. RESULTS The UCMS exacerbated depressive-like behavior in PS2 mutant mice In this study, we induced UCMS in the PS2 WT and MT mice for 28 consecutive days. After 28 days of stress, a series of behavioral tests were performed to validate depressive-like behavior, learning ability, and memory in these mice (Fig. 1A). To evaluate anhedonia, which is a core symptom of depressive behavior, the SPT was conducted. UCMS significantly reduced the SPT in PS2 MT mice, moreover, the SPF was significantly decreased in the PS2 MT-UCMS mice compared to the PS2 WT-UCMS mice [Fig. 1B: n=4 per group; FTg(1,12)=10.503, p=0.007; FUCMS(1,12)=14.997, p=0.002; FTg×UCMS(1,12)=0.736, p=0.408]. The TST and FST showed the same trend as SPF, with a significant increase in immobility time between the PS2 WT-Con and PS2 MT-Con mice [Fig. 1C: n=4 per group; FTg(1,12)=17.299, p=0.001; FUCMS(1,12)=9.129, p=0.011; FTg×UCMS(1,12)=0.814, p=0.385] [Fig. 1D: n=4 per group; FTg(1,12)=97.500, p<0.001; FUCMS(1,12)=6.678, p=0.024; FTg×UCMS(1,12)=4.338, p=0.059]. Here, the PS2 MT mice exhibited memory impairment in comparison to the paired PS2 WT mice, furthermore, elevated levels of Aβ1-42, total Tau, and p-Tau proteins, which are known to cause AD, were observed in the PS2 MT mice relative to the PS2 WT mice. This phenomenon was further exacerbated by stress (Supplementary Fig. 1). These results indicate that stress accelerates depressive-like behaviors in PS2 MT-AD model mice. Stress-induced depressive-like behaviors in PS2 mutant mice. (A) The timeline shows the experimental schedule for UCMS, depression-related behavior tests, and AD-related behavior tests. Validation of depression-related behaviors in mice via the (B) sucrose preference test (SPT), (C) tail suspension test (TST), and (D) forced swimming test (FST). Depression-like behaviors in PS2 WT-Con mice, UCMS-induced PS2 WT mice, PS2 MT-Con mice and UCMS-induced PS2 MT mice were evaluated by the percentage of sucrose preference in the SPT (%), total duration of immobility in the TST (s), and total duration of immobility time in the FST (s). Data are presented as mean ± SE (n=4) and analyzed using two-way ANOVA followed by the Holm–Sidak post hoc test (*p<0.05). UCMS, unpredictable chronic mild stress; AD, Alzheimer’s disease; WT, wild-type; Con, control; MT, mutant-type. Notch2 expression correlated with depression and AD Gene expression profiles based on GEO database analysis were used to analyze Notch2 expression in AD and depression. Comparing NOTCH2 gene expression in the hippocampus, we found that in the GSE1297 dataset, the AD group (n=15) increased approximately 1.63-fold (log2FC=0.7053) compared to the control group (n=9; Fig. 2A), and in the GSE42546 dataset, the depression group (n=17) increased approximately 1.47-fold (log2FC=0.5590) compared to the control group (n=29; Fig. 2B). To confirm the relationship between Notch2, AD, and depression, we performed analysis of inference score from the CTD (https://ctdbase.org). An inference analysis of Notch2 across neurological disorders revealed that the highest score was observed for memory disorders (133.97), followed by nerve degeneration (128.03) and learning disabilities (122.4). In addition, inference scores for anxiety disorders (118.02) and depressive disorders (96.61) followed impairments related to neurocognitive and neurodegenerative disorders (Fig. 2C). We also found a correlation between Notch2 gene and a gene known to be associated with AD (App, Psen2) and a gene known to be associated with depression (Bdnf, Nr3c1) through gene mania analysis (https://genemania.org) (Fig. 2D). These findings suggest that Notch2 may be implicated in neurocognitive functions, neurodegenerative processes, and depression-related pathways. Notch2 correlates in AD and depression. (A, B) Volcano plots were generated using GEO2R with Benjamini–Hochberg FDR correction (cut-off<0.05), no limma precision weights, and a |log2FC|>0.5. (A) GSE1297 is hippocampal samples from AD group (n=15) versus control group (n=9). (B) GSE42546 is hippocampal samples from depression group (n=17) versus control group (n=29). On each plot, the x-axis represents log2FC and the y-axis represents –log10(p-value). Significantly upregulated transcripts (log2FC>0.5, p<0.05) are shown in red, significantly downregulated transcripts (log2FC<–0.5, p<0.05) in blue, non-significant genes in black, NOTCH2 gene in purple, and NOTCH1, NOTCH3, and NOTCH4 gene in grey. (C) Inference scores for Notch2 and diseases were obtained from CTD web portal (https://ctdbase.org). The top eight disease categories are displayed as horizontal bars, with inference score on the x-axis. AD-related diseases are shown in red, depressive disease in blue, other nervous system-related diseases in white. (D) Using the GeneMANIA (https://genemania.org/) web portal, Notch2, Nr3c1, Bdnf, App, and Psen2 were entered as query genes. The resulting network displays genes as nodes, with node size proportional to the degree of connectivity. Bolded red lines highlight direct interactions between Notch2 and each co-query gene (Nr3c1, Bdnf, App, Psen2). FDR, false discovery rate; AD, Alzheimer’s disease; FC, fold change; CTD, comparative toxicogenomics database. UCMS elevated GR pathway and γ-secretase activity in PS2 mutant mice through Notch2 signaling Hypersecretion of GCs is considered a major biological risk factor of depression (Chojnowska et al., 2021). Furthermore, phosphorylation of GRs on one of many serine residues is required to bind with GCs (Ismaili and Garabedian, 2004). Therefore, in the case of depression, GR phosphorylation is increased by high levels of GCs (Pariante and Miller, 2001; Rogatsky et al., 1998). An ELISA assay was performed to measure the corticosterone levels in the mice plasma. Corticosterone levels were significantly elevated by UCMS within the PS2 MT pair. Under non-stressed conditions, corticosterone levels were higher in PS2 MT-Con mice compared with PS2 WT-Con mice, and this genotyped-dependent increase persisted following UCMS [Fig. 3A: n=4 per group; FTg(1,12)=40.643, p<0.001; FUCMS(1,12)=7.891, p=0.016; FTg×UCMS(1,12)=2.228, p=0.161]. γ-Secretase activity and Notch2 mRNA expression exhibited parallel trends to corticosterone levels across all experimental groups [Fig. 3B: n=4 per group; FTg(1,12)=70.934, p<0.001; FUCMS(1,12)=32.632, p<0.001; FTg×UCMS(1,12)=21.055, p<0.001] [Fig. 3C: n=3 per group; FTg(1,8)=18.035, p=0.003; FUCMS(1,8)=6.261, p=0.037; FTg×UCMS(1,8)=0.705, p=0.425]. In hippocampal lysates, Western blot quantification demonstrated that total GR and p-GR levels were elevated in PS2 MT-Con versus PS2 WT-Con mice and further augmented by UCMS in PS2 MT mice [Fig. 3Da: n=3 per group; FTg(1,8)=9.873, p=0.014; FUCMS(1,8)=7.109, p=0.029; FTg×UCMS(1,8)=1.685, p=0.230] [Fig. 3Db: n=3 per group; FTg(1,8)=5.813, p=0.042; FUCMS(1,8)=6.390, p=0.035; FTg×UCMS(1,8)=0.620, p=0.454]. Likewise, expression of Notch2-FL and Notch2-NTM showed the same pattern as p-GR, reaching maximal levels in PS2 MT-UCMS mice hippocampus [Fig. 3Dc: n=3 per group; FTg(1,8)=6.076, p=0.039; FUCMS(1,8)=15.539, p=0.004; FTg×UCMS(1,8)=7.620, p=0.025] [Fig. 3Dd: n=3 per group; FTg(1,8)=16.745, p=0.003; FUCMS(1,8)=34.478, p<0.001; FTg×UCMS(1,8)=10.508, p=0.012]. These results show that PS2 MT shows amplification on stress- and AD-related markers, and expression of Notch2 under UCMS. UCMS-induced potentiation of corticosterone level, γ-secretase activity, and Notch2 signaling in PS2 mutant mice. (A) Corticosterone level in mice plasma measured by ELISA. Data are presented as mean ± SE (n=4) and analyzed using two-way ANOVA followed by the Holm–Sidak post hoc test (*p<0.05). (B) γ-Secretase activity in mice hippocampal lysates measured by using specific kit, and presented as relative fluorescence units (RFU). Data are presented as mean ± SE (n=4) and analyzed using two-way ANOVA followed by the Holm–Sidak post hoc test (*p<0.05). (C) Relative Notch2 mRNA expression in mice hippocampus assessed by RT-qPCR (fold change vs. PS2 WT-Con group). Data are presented as mean ± SE (n=3) and analyzed using two-way ANOVA followed by the Holm–Sidak post hoc test (*p<0.05). (D) Western blot analysis of hippocampal lysates show levels of total GR, p-GR, Notch2-FL, and Notch2-NTM. β-actin served as a loading control. (a-d) Adjacent bar graphs depict densitometric quantification of (a) GR, (b) p-GR, (c) Notch2-FL, and (d) Notch2-NTM normalized to β-actin, and data are presented as mean ± SE (n=3) and analyzed using two-way ANOVA followed by the Holm–Sidak post hoc test (*p<0.05). UCMS, unpredictable chronic mild stress; WT, wild-type; MT, mutant-type; GR, glucocorticoid receptor; p-GR, phosphorylated GR; Notch2-FL, full-length Notch2; Notch2-NTM, Notch2 transmembrane/intracellular region. Depressive-like behaviors were ameliorated in DAPT-treated PS2 mutant mice To confirm that Notch2 is a critical target for depression in PS2 MT mice, we used DAPT which is an inhibitor of γ-secretase and a potent Notch signaling pathway. PS2 WT and MT mice were subcutaneously administered vehicle (10 mL/kg) or DAPT (100 mg/kg) daily for 14 days. After 14 days of stress, a series of behavioral tests were performed to validate depressive-like behavior, learning ability, and memory in these mice (Fig. 4A). DAPT restored SPF in PS2 MT-DAPT mice to levels comparable to PS2 WT mice, and significantly higher than PS2 MT-Vehicle mice [Fig. 4B: n=5 per group; FTg(1,16)=22.432, p<0.001; FDAPT(1,16)=13.981, p=0.002; FTg×DAPT(1,16)=15.146, p=0.001]. In TST and FST, the immobility time of mice were induced in PS2 MT-Vehicle mice compared to PS2 WT-Vehicle mice, however, DAPT administration significantly decreased immobility time in PS2 MT mice [Fig. 4C: n=5 per group; FTg(1,16)=17.183, p<0.001; FDAPT(1,16)=27.398, p<0.001; FTg×DAPT(1,16)=17.919, p<0.001] [Fig. 4D: n=5 per group; FTg(1,16)=19.371, p<0.001; FDAPT(1,16)=3.043, p=0.100; FTg×DAPT(1,16)=11.621, p=0.004]. Here, The PS2 MT-Vehicle mice showed induced memory impairment through symptoms such as longer escape latency, distance, and percent of time spent in target quadrant than PS2 WT-Vehicle mice (Supplementary Fig. 2A-2C). Moreover, in Y-maze test, PS2 MT-Vehicle mice had significant working memory deficit, with reduced alternation rates compared to PS2 WT-Vehicle mice (Supplementary Fig. 2D), and these memory impairments and working memory deficits were reversed by DAPT administration. These results indicate that administration of DAPT, a Notch signaling inhibitor, alleviates depression-like behaviors and cognitive deficits in PS2 MT mice. Inhibitory effects of DAPT on PS2 mutant-induced depressive-like behaviors in mice. (A) The timeline shows the administration schedule of DAPT, depression-related behavior tests, and AD-related behavior tests. Validation of depression-related behavior in mice via the (B) sucrose preference test (SPT), (C) tail suspension test (TST), and (D) forced swimming test (FST). Depression-like behaviors in PS2 WT-Vehicle mice, PS2 WT-DAPT mice, PS2 MT-Vehicle mice and PS2 MT-DAPT mice were evaluated by the percentage of sucrose preference in the SPT (%), total duration of immobility in the TST (s), and total duration of immobility time in the FST (s). Data are presented as mean ± SE (n=5) and analyzed using two-way ANOVA followed by the Holm–Sidak post hoc test (*p<0.05). DAPT, γ-secretase inhibitor; WT, wild-type; MT, mutant-type. DAPT administration attenuated GR pathway and γ-secretase activity in PS2 mutant mice through inhibition of Notch2 signaling In PS2 MT mice, administration of DAPT significantly reduced basal plasma corticosterone from 749.66 ± 31.71 ng/mL (PS2 MT-Vehicle) to 519.90 ± 47.62 ng/mL (PS2 MT-DAPT), a level similar to that of PS2 WT mice [Fig. 5A: n=5 per group; FTg(1,16)=49.985, p<0.001; FDAPT(1,16)=4.731, p=0.045; FTg×DAPT(1,16)=18.740, p<0.001]. Hippocampal γ-secretase activity decreased from 171.74 ± 2.61 RFU to 150.85 ± 1.12 RFU in PS2 MT-DAPT mice, with no effect in PS2 WT mice [Fig. 5B: n=5 per group; FTg(1,16)=24.720, p<0.001; FDAPT(1,16)=29.010, p<0.001; FTg×DAPT(1,16)=15.582, p=0.001]. Hippocampal Notch2 mRNA expression in PS2 MT-Vehicle mice (2.57 ± 0.19-fold over PS2 WT-Vehicle mice) was reduced by 42.92% in PS2 MT-DAPT mice (1.47 ± 0.12-fold over PS2 WT-Vehicle mice) [Fig. 5C: n=5 per group; FTg(1,16)=41.817, p<0.001; FDAPT(1,16)=11.021, p=0.004; FTg×DAPT(1,16)=17.090, p<0.001]. In hippocampal lysates, compared with vehicle-treated PS2 MT mice, DAPT-treated PS2 MT mice exhibited a pronounced reduction in total GR protein, bringing GR/β-actin ratios down to PS2 WT levels, and similarly attenuated p-GR [Fig. 5Da: n=3 per group; FTg(1,8)=8.210, p=0.021; FDAPT(1,8)=0.771, p=0.406; FTg×DAPT(1,8)=6.829, p=0.031] [Fig. 5Db: n=3 per group; FTg(1,8)=93.338, p<0.001; FDAPT(1,8)=17.004, p=0.003; FTg×DAPT(1,8)=87.603, p<0.001]. Concurrently, both Notch2-FL and Notch2-NTM were significantly diminished in PS2 MT-DAPT mice relative to PS2 MT-Vehicle mice [Fig. 5Dc: n=3 per group; FTg(1,8)=38.411, p<0.001; FDAPT(1,8)=0.0978, p=0.763; FTg×DAPT(1,8)=41.511, p<0.001] [Fig. 5Dd: n=3 per group; FTg(1,8)=6.290, p=0.036; FDAPT(1,8)=1.158, p=0.313; FTg×DAPT(1,8)=12.920, p=0.007]. Therefore, in PS2 mutant hippocampus, we found that DAPT effectively inhibited GR and Notch2 pathway activation. In addition, these findings demonstrated that Notch2 signaling functions as a causal mediator of both cognitive deficits and depressive-like behaviors in PS2 MT mice. Inhibitory effects of DAPT on corticosterone level, γ-secretase activity, and Notch2 signaling in PS2 mutant mice. (A) Corticosterone level in mice plasma measured by ELISA. Data are presented as mean ± SE (n=5) and analyzed using two-way ANOVA followed by the Holm–Sidak post hoc test (*p<0.05). (B) γ-Secretase activity in mice hippocampal lysates measured by using specific kit, and presented as relative fluorescence units (RFU). Data are presented as mean ± SE (n=5) and analyzed using two-way ANOVA followed by the Holm–Sidak post hoc test (*p<0.05). (C) Relative Notch2 mRNA expression in mice hippocampus assessed by RT-qPCR (fold change vs. PS2 WT-Vehicle group). Data are presented as mean ± SE (n=5) and analyzed using two-way ANOVA followed by the Holm–Sidak post hoc test (*p<0.05). (D) Western blot analysis of hippocampal lysates show levels of total GR, p-GR, Notch2-FL, and Notch2-NTM. β-actin served as a loading control. (a-d) Adjacent bar graphs depict densitometric quantification of (a) GR, (b) p-GR, (c) Notch2-FL, and (d) Notch2-NTM normalized to β-actin, and data are presented as mean ± SE (n=3) and analyzed using two-way ANOVA followed by the Holm–Sidak post hoc test (*p<0.05). DAPT, γ-secretase inhibitor; WT, wild-type; MT, mutant-type; GR, glucocorticoid receptor; p-GR, phosphorylated GR; Notch2-FL, full-length Notch2; Notch2-NTM, Notch2 transmembrane/intracellular region. DISCUSSION Epidemiological studies show that depression significantly increases the risk of developing AD, with depressive symptoms observed in up to 50% of AD patients (Lindsay et al., 2002; Singh-Manoux et al., 2017). Chronic stress has been consistently linked to the onset and progression of depressive episodes, reinforcing stress as a critical factor in depression pathology (Aznar and Knudsen, 2011; Caraci et al., 2010). In our previous study, Tg2576 mice were more prone to depressive behaviors than WT mice (Yoo et al., 2025). Additionally, PS2 MT mice are known to experience more severe memory dysfunction relative to their WT counterparts, suggesting a potential link between depressive symptoms and AD progression (Gold, 2015; Hwang et al., 2002, 2016; Lee et al., 2011). Meanwhile, in a clinical study, early life stress in children was associated with an increased risk of depression (Heim and Nemeroff, 2001). Moreover, many studies show that chronic stress leads to the development of depression in mice (Strekalova et al., 2005; Strekalova and Steinbusch, 2010). Therefore, in this study, we used the PS2 MT-AD mice model to assess whether stress promotes depression and to find pathways that may link AD and depression. In present study, UCMS was used to induce depression. The UCMS protocol is an established translationally-relevant model for inducing behavioral symptoms commonly associated with clinical depression, such as anhedonia, altered grooming behavior, and learned helplessness in rodents (Farooq et al., 2012; Frisbee et al., 2015). Behavioral tests showed that PS2 mutant mice exposed to UCMS exhibited a marked decrease in sucrose preference and increased immobility in the TST and FST compared to PS2 WT-UCMS mice (Fig. 1B, 1C). These results are consistent with the hypothesis that neurodegenerative pathology sensitizes the brain to mood disorders (Galts et al., 2019; Levenson et al., 2014; Wingo et al., 2022), and indicate increased vulnerability to stress-induced depression-like behavior in AD models. Importantly, these behavioral deficits were paralleled by elevations in plasma corticosterone, the biological glucocorticoid in mouse, and increased phosphorylation of GR in mice hippocampus (Fig. 3A, 3Db). Both AD and depression involve synaptic degeneration, often exacerbated by elevated glucocorticoid levels (Wuwongse et al., 2013). Chronic stress stimulates the hypothalamic secretion of CRF and AVP, subsequently triggering ACTH release from the pituitary gland. This cascade increases glucocorticoid secretion from the adrenal cortex. Elevated glucocorticoid levels activate GR, impairing hippocampal neurogenesis, promoting neuronal death, and reducing hippocampal volume (Frodl and O’Keane, 2013; Krishnan and Nestler, 2008; Pariante and Lightman, 2008; Sapolsky, 1986). Consequently, plasma glucocorticoid and hippocampal GR levels are biomarkers indicative of stress-related depression, and in this study, these markers were most elevated in PS2 MT-UCMS mice. Given that chronic stress-induced cortisol elevation is a recognized depression risk factor, these findings imply elevated corticosterone levels likely mediate severe depressive symptoms observed in PS2 MT-UCMS mice (Goodyer et al., 2000; Guilliams and Edwards, 2010; Harris et al., 2000). Gene expression analyses of human hippocampal tissue from both AD and depression patients demonstrated a significant upregulation of NOTCH2 (Fig. 2A, 2B). By using the CTD database, we found that AD- and depression-related symptoms were ranked in the top ten based on inference scores in the neurocognitive and mood disorder pathways (Fig. 2C), moreover, network-based approaches (GeneMania) identified Notch2 as a hub gene associated with AD (App, Psen2) and depression (Bdnf, Nr3c1) (Fig. 2D). On the other hand, PS2 is the core catalytic protein of γ-secretase, and the γ-secretase complex must contain either PS1 or PS2 to have enzymatic activity (Steiner, 2008; Zhang et al., 2013, 2014). In neurons from N141I mutant PS2 mice, γ-secretase activity is increased compared to WT mice (Yun et al., 2016). γ-Secretase is also involved in the activation of Notch2, where the Notch2 intracellular domain (NICD2) generated from γ-secretase-cleaved Notch2 is transcribed into the nucleus and regulates gene expression (Henrique and Schweisguth, 2019; Kopan and Goate, 2000; Martin et al., 2023; Sprinzak and Blacklow, 2021). In our study, γ-secretase activity and Notch2 signaling activation were increased in the hippocampus of PS2 MT mice, and chronic stress further upregulated these changes (Fig. 3B-3D). This upregulation may provide a molecular basis for the exacerbation of memory impairment and increased levels of key AD-associated proteins, such as Aβ1-42, total Tau, and p-Tau, observed in PS2 MT-UCMS mice (Supplementary Fig. 1). It is noteworthy that while UCMS may alter GR and Notch2 expression in WT mice to some extent, depressive-like behaviors were exclusively observed in PS2 MT mice. This suggests that the elevation of these molecular markers alone is not sufficient to induce behavioral deficits in a healthy neural environment. Rather, the pre-existing neurodegenerative pathology, driven by the N141I mutation and subsequent Aβ/Tau accumulation, sensitizes the brain, creating a vulnerable background where stress-induced Notch2 and GR signaling synergistically push the brain past the threshold for depressive-like behaviors. Importantly, GR/p-GR/Notch2 upregulation alone is not sufficient in WT; behavioral expression requires PS2-dependent vulnerability and coordinated pathway activation. To confirm that Notch2 is a critical target for both AD and depression, we used DAPT to inhibit not only γ-secretase activity but also the Notch signaling pathway (Wang et al., 2019). The administration of DAPT resulted in significant enhancements in depressive-like behaviors and cognitive performance, as well as the normalization of corticosterone levels, the reduction of GR phosphorylation, and the decrease of Notch2 expression in the hippocampus (Fig. 4, 5, Supplementary Fig. 2). These results suggest that Notch2 is associated with, and functions as a mediator of, the behavioral and molecular abnormalities induced by chronic stress in the AD model. Interestingly, DAPT administration had opposing molecular effects on Notch2 and GR expression in the WT and PS2 MT mice (Fig. 5D). In WT mice, γ-secretase inhibition may trigger a compensatory homeostatic feedback loop, resulting in a slight upregulation of Notch2 and GR as the healthy brain attempted to overcome the pharmacologic blockade. In contrast, in PS2 MT mice, in which γ-secretase is pathologically overactivated due to the N141I mutation, DAPT effectively blocked the vicious cycle of stress and excessive signaling. This targeted normalization of aberrant pathways explains the marked reduction in Notch2 and GR levels in MT mice, highlighting the context-dependent therapeutic effects of γ-secretase modulators in neurodegenerative diseases. These findings highlight the importance of Notch2 signaling as a molecular intersection between AD pathology and stress-induced depression-like behavior, and suggest that therapeutic strategies targeting Notch2 may be beneficial for both neurodegenerative and mood disorders. In particular, the efficacy of DAPT in improving both depressive and cognitive symptoms highlights the therapeutic potential of modulating Notch2 signaling. Some limitations should be acknowledged. This study was conducted in a single genetic model of AD, and the sample size for behavioral and molecular analyses was modest. Further studies using additional models and larger cohorts are needed to generalize these findings. Moreover, the downstream molecular events linking Notch2 to GR signaling are not yet fully understood. Furthermore, because DAPT is not selective for Notch2, it will process multiple substrates including APP and other Notch isoforms (Notch1-4) (Bittner et al., 2009). Consequently, the therapeutic effect of DAPT observed in this study is likely attributable to the broad regulation of these parallel pathways. Despite this non-selectivity, the present study placed a high priority on Notch2 signaling based on compelling transcriptomic and bioinformatic evidence. In contrast to other isoforms, WGCNA analysis revealed Notch2 as a key hub gene in AD, specifically upregulated in chronic stress models (Liang et al., 2018; Liao et al., 2021). In addition, our analysis of human hippocampal datasets (GSE1297 and GSE42546) additionally demonstrated that NOTCH2 is uniquely increased in both AD and depression. While future studies utilizing Notch2-specific conditional knockout models are needed to clearly define its individual contribution, the findings of the present study, supported by existing literature, suggest that Notch2 represents a highly relevant molecular intersection between AD pathology and stress-induced depressive behavior. In conclusion, this study establishes Notch2 as a pivotal mediator linking chronic stress, depression-like behaviors, and AD pathology. By demonstrating that inhibition of Notch2 signaling can reverse both behavioral and molecular deficits in AD models, our findings can suggest a promising direction for the development of targeted therapies for the comorbidity of AD and depression. ACKNOWLEDGMENTS This work was financially supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (No. RS-2025-02273102), the Bio&Medical Technology Development Program of the NRF funded by the Korea government (MSIT) (No. RS-2024-00440787), and Basic Science Research Program through the NRF funded by the Ministry of Education (RS-2024-00460411). Footnotes CONFLICT OF INTEREST The authors declare no competing interests. AUTHOR CONTRIBUTIONS Seung Sik Yoo: Investigation, Data curation, Visualization, Writing – original draft. Sun Mi Gu: Formal Analysis, Investigation, Visualization, Writing – original draft, Funding acquisition. Kyung Tak Nam: Formal Analysis, Visualization, Writing – original draft. Jeong Soon Choi: Formal Analysis, Visualization, Writing – original draft. Yong Sun Lee: Formal Analysis, Visualization. In Jun Yeo: Formal Analysis, Visualization. Ji Eun Yu: Investigation, Data curation. Sanghyeon Kim: Data curation, Visualization. Dong Won Lee: Data curation, Visualization. Hyeon Joo Ham: Investigation, Formal Analysis. Ju Young Chang: Investigation, Formal Analysis. Jaesuk Yun: Resources, Writing – review & editing. Dong Ju Son: Resources, Writing – review & editing. Sang-Bae Han: Conceptualization, Supervision, Project administration, Resources, Funding acquisition. Jin Tae Hong: Conceptualization, Supervision, Project administration, Resources, Writing – review & editing. REFERENCES Associated Data Supplementary Materials